



Bulletin from the Annual General Meeting of Redsense Medical AB (publ) on May 20, 2026

Redsense Medical AB (publ) (“Redsense Medical” or the “Company”) held its Annual General Meeting (the “AGM”) on Wednesday May 20, 2026, in Halmstad, at which the following main resolutions were adopted. All resolutions were passed with the required majority. For detailed information regarding the content of the resolutions, please refer to the notice of the AGM and the complete proposals available on the Company's website, www.redsensemedical.com.

Appropriation of the result

The AGM resolved, in accordance with the Board of Directors' amended proposal, that the distributable funds shall be allocated so that SEK 32,043,031 shall be carried forward.

Discharge from liability for the members of the Board of Directors and the CEO

The AGM resolved to discharge the members of the Board of Directors and the CEO from liability for the financial year 2025.

The Board of Directors and the auditor

The AGM resolved, in accordance with the Nomination Committees' proposal, to re-elect Susanne Olauson, Johannes Köppler, Mike Griffiths and Martin Roos, and to elect Michael Kraus as Directors for the period until the end of the next AGM. Furthermore, the AGM re-elected Susanne Olauson as Chair of the Board for the period until the end of the next AGM.

More information about elected board members is available on the Company's website, www.redsensemedical.com.

The AGM resolved, in accordance with the Nomination Committees' proposal, to re-elect the registered audit Company Azets Revision och Rådgivning AB as auditor, with the authorized accountant Andreas Johansson as the auditor-in-charge.

As remuneration to the Board of Directors for the period until the next AGM, the AGM resolved, in accordance with the Nomination Committees' proposal, that remuneration shall be paid with SEK 250,000 to the Chairman of the Board and SEK 125,000 to each of the other Board members.

The AGM resolved, in accordance with the Nomination Committees' proposal, that remuneration to the auditor shall be paid in accordance with approved invoices.

Issue authorization

The AGM resolved, in accordance with the Board of Directors' proposal, to authorize the Board of Directors to, on one or more occasions and with or without deviation from the shareholders' preferential rights, up to the next AGM, decide on issues of shares, warrants, and/or convertibles. By decision supported by the authorization, a maximum number of shares may be issued in the event of a new issue of shares, through the exercise of warrants and/or when converting convertibles, that corresponds to 20 percent of the total number of outstanding shares in the Company at the time when the authorization is exercised for the first time.

Contact information

For more information, please contact:
Sebastien Bollue, CEO
Telephone: +46 72-171 1264
E-mail: sebastien.bollue (at) redsensemedical.com

Redsense Medical AB (publ), 556646-4862

About Redsense Medical

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS).